PCOS Notes

by Alexander Mauskop, MD, Anne Richards, Aviva Romm, MD, Brian Martin, PhD, Carolina Stephany Gonzalez, MD, Cheri King, ND, David Fairbrook, MD, Elaine Weil, NP, CNC, Howard Straus, Marianne Marchese, ND, Melissa Burchill, RD, CDN, Richard S. Lord, PhD | Apr 1, 2015

Post Categories: Hormone and Metabolic Health | Menstrual Health | Reproductive Health

Notes

Marchese M. Polycystic ovarian syndrome: a natural treatment approach. Townsend Lett. Feb/March 2012:66–68.
Guzick D. Polycystic ovarian syndrome. Obstet Gynecol. 2004;103(1):181–193.
Romm A. Botanical Medicine for Women’s Health. St. Louis: Churchill Livingstone/Elsevier; 2010:175–185.
Wei A et al. Therapy for polycystic ovarian syndrome. Curr Opin Pharmacol. 2003;3:678–682.
Ring M. Polycystic ovarian syndrome. In: Rakel D. Integrative Medicine. 3rd ed. Philadelphia: Elsevier;2012:345–352.
Azziz R. Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril. 2003;80:252–254.

Advertisement
Azziz R et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–2782.
Balen A et al. Polycystic ovary syndrome: the spectrum of this disorder in 1741 patients. Hum Reprod. 1995;10:2107–2111.
Book C et al. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 199;84(9):3110–3116.
Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin dependent diabetes mellitus. Am J Med. 1995;98:33S–39S.
Tsilchorozidou T et al. The pathophysiology of polycystic ovary syndrome.
Clin Endocrinol (Oxf). 2004;60:1–17.
Richardson M. Current perspective in polycystic ovary syndrome. Am Fam Physician. 2003;68(4):697–704.
Alexander C. Polycystic ovary syndrome: a major unrecognized cardiovascular risk factor in women. Rev Obstet Gynecol. 2009;2(4):232–239.
Marchese. Op cit.
Speroff. Op cit.
Solomon C. The epidemiology of polycystic ovary syndrome: prevalence and associated disease risks. Endocrinol Metab Clin North Amer. 1999;28(2):247–263.
Fraser I et al. Current recommendations for the diagnostic evaluation and follow-up of patients presenting with symptomatic polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18(5):813–823.
Ahene S et al. Polycystic ovary syndrome. Nurs Stand. 2004;18(26):40–44.
Futterweit W. A Patient’s Guide to PCOS. New York: Henry Holt and Company; 2006.
Marchese. Op cit.
Carmina E. Diagnosing PCOS in women who menstruate regularly. Contemp Obstet Gynecol. 2003;53–64.
Marchese. Op cit.
Hill, K., Update: the pathogenesis and treatment of PCOS. Nurse Pract 2003;28:8–25.
Romm. Op cit.
Marchese. Op cit.
Pritts E. Treatment of the infertile woman with polycystic ovarian syndrome. Obstet Gynecol Surv. 2002;57:587–597.
Futterweit. Op cit.
Atimo W et al. Familial associations in women with polycystic ovary syndrome. Fertil Steril. 2003;80(1):143–145.
Gonzalez C et al. Polycystic ovaries in childhood: a common finding in daughters of PCOS patients of PCOS patients. A pilot study. Hum Reprod. 2002;17(3):771–776.
Govind A et al. Polycystic ovaries are inherited as an autosomal dominant trait: an analysis of 29 polycystic ovary and 10 control families. J Clin Endocrinol Metab. 1999;84:38043.
Futterweit. Op cit.
Azziz R et al. Family history as a risk factor for the polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2000;13:1303–1306.
Strauss J et al. Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome. Ann NY Acad Sci. 2003;997:42–48.
Carey A et al. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol. 38(6):653–658.
Urbanek M et al. Thirty seven candidate genes for PCOS: Strongest evidence of linkage is follistatin. Proc Nat Acad Sci. 1999;38(6):653–658.
King J. Polycystic ovarian syndrome. J Midwifery Womens Health. 2006;51(6):415–422.
King. Ibid.
Tsilchorozidou. The pathophysiology of polycystic ovary syndrome. 2004. Op cit.
Marchese. Op cit.
Speroff. Op cit.
Romm. Op cit.
Speroff. Op cit.
Hopkinson Z et al. Polycystic ovarian syndrome: the metabolic syndrome comes to gynecology. BMJ. 1998;317:329–332.
Marchese. Op cit.
Romm. Op cit.
Marantides D et al. Management of polycystic ovary syndrome. Nurse Pract. 1997;22(12):34–38,40–41.
Tsilchorozidou T et al. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. J Clin Endocrinol Metab. 2004;88(12):5907–5913.
Barnea E et al. Stress-related reproductive failure. J In Vitro Fert Embryo Transf. 1991;8:15–23.
Tsilchorozidou T et al. The pathophysiology of polycystic ovarian syndrome. 2004. Op cit.
Lindsay A et al. Multicystic ovaries in primary hypothyroidism. Obstet Gynecol. 1983;61:433–437.
Ghosh S et al. Subclinical hypothyroidism: a determinant of polycystic ovary syndrome. Horm Res. 1993;39:61–66.
McNamara D. Thyroiditis rate three-fold higher with PCOS. Fam Pract News. 2004;Mar 1:75.
Marchese. Op cit.
Chang R et al. Normal ovulatory women with polycystic ovaries have hypoandrogenic pituitary-ovarian responses to gonadotropin-releasing hormone-agonist testing. J Clin Endocrinol Metab. 2000;85(3):995–1000.
Pelusi B et al. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol. 2004;56(1):41–51.
Talbott E et al. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Amer. 2001;28(1):111–133.
Rajkhowa M et al. Polycystic ovary syndrome: a risk for cardiovascular disease. BJOG. 2000;107(1):11–18.
Trent M et al. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome: implications for quality of life. J Pediatr Adolesc Gynecol. 2003;16(1):33–37.
Radulovic A et al. Obesity and hormone function changes in female patients with polycystic ovaries. Med Pregl. 2003;56(9–10):476–480.
Gonzalez, C et al. Polycystic ovarian disease: clinical and biochemical expression. Ginecol Obstet Mex. 2003;71:253–258.
Pelusi B et al. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol. 2004;56(1):41–51.
Legro R et al. Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metabol. 1999;84(1):165–169.
De Leo, V et al. Polycystic ovary syndrome and type 2 diabetes mellitus. Minerva Ginecol. 2004;56(1):53–62.
Solomon C et al. Long or irregular menstrual cycle as a marker for the risk of type 2 diabetes mellitus. JAMA. 2001;286(19):2421–2426.
Solomon. Op cit.
Danaif A et al. Beta cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 1996;81:942–947.
Christian R et al. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(6):2562–2568.
Wild S et al. Cardiovascular disease in women with PCOS: A long-term follow up: A retrospective cohort study. Clin Endocrinol (Oxf). 2000;52(5):595–600.
Talbot, E et al. Cardiovascular risk in women with polycystic ovary syndrome. Obstet Gynecol Clin North Amer. 2001;28(1):111–133.
Marchese. Op cit.
Orio F et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab. 2004;89(8):3696–3701.
Marchese. Op cit.
Chang R. A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol. 2004;191:713–717.
Phelan N et al. Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) compared with equally insulin-resistant women without PCOS. J Clin Endocrinol Metab. 2010;95(8):3933–3939.
Wild R et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) society. Fertil Steril. 20011;95(3):1073–79.
Ehrmann D. Polycystic ovarian syndrome. N Eng J Med. 2005;353:1223–1236.
Romm. Op cit.
Loverro G et al. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest. 2002;53(3):157–162.
Boulman N et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metabol. 2004;89(5):2160–2165.
Fenkev I et al. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril. 2003;8091):123–127.
Lefebvre, P et al. Long-term risks of polycystic ovaries syndrome. Gynecol Obstet Fertil. 2004;32(3):193–198.
Landsberg M. Insulin sensitivity in the pathogenesis of hypertension and hypertensive complications. Clin Exp Hypertens. 1996;18(3–4):337–346.
Milsom S et al. LH levels in women with polycystic ovarian syndrome: have modern assays made them irrelevant? BJOG. 2003;110(8):760–764.
Franks S. The ubiquitous polycystic ovary. J Endocrinol. 1991;129:317–319.
Diejomaoh M et al. The relationship of recurrent spontaneous miscarriage with reproductive failure. Med Princ Pract. 2003;12(2):107–111.
Rai R et al. Polycystic ovaries and recurrent miscarriage – a reappraisal. Hum Reprod. 2000;15:612–615.
Hardiman P et al. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361(9371):1810–1812.
Spremovi R et al. The polycystic ovary syndrome associated with ovarian tumor. Srp Arh Celok Lek. 1997;125 (11–12):375–377.
Wild S et al. Long-term consequences of polycystic ovary syndrome: results of a 31-year study. Hum Fertil (Camb). 2000;3(2):101–105.
Robinson S et al. Postprandial thermogenesis is reduced in polycystic ovary syndrome and is associated with increased insulin resistance. Clin Endocrinol (Oxf). 1992;36(6):537–543.
Faloia E et al. Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2004;27(5):424–429.
Gambineri A et al. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002;26(7):883–896.
Romm. Op cit.
Wei. Op cit.
Richardson. Op cit.
Speroff. Op cit.
Guzick D. Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology. Am J Obstet Gynecol. 1998;196(6 Pt. 2):S89–S93.
D’Hooghe T et al. Infertility. In: Novak’s Gynecology. Philadelphia: Lippincott Williams & Wilkins; 2002.
Fleming R et al. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double-blind placebo controlled trial. J Clin Endocrinol Metabol. 2003;87(2):557–569.
Lord J et al. Insulin-sensitizing drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovarian syndrome. Cochrane Database Syst Rev. 2003:3:(CD003053).
McCarthy E et al. Metformin in obstetric and gynecologic practice: a review. Obstet Gynecol Surv. 2004; Huber-Buchholz M et al. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84(4):1470–1474.
Anderson J et al. Dietary fiber: diabetes and obesity. Am J Gasteroenterol. 1986;81:898–906.
Burke V. Dietary protein and soluble fiber reduce ambulatory blood pressure in treatment of hypertensives. Hypertension. 2001;38(4):821–826.
Sprecher D et al. efficacy of psyllium in reducing serum cholesterol levels in hypercholesterolemic patients on high-or low-fat diets. Ann Inter Med. 1993;119:545–554.
Huber-Buchholz. Op cit.
Richardson. Op cit.
Romm. Op cit.
Solomon. Op cit.
D’Hooghe. Op cit.
Crosignani P et al. Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate by diet. Human Reprod. 1932;18(9):1928–1932.
Jakubowicz D et al. 17-alpha-hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metabol. 1997;82(2):556–560.
Kahn J et al. Polycystic ovary syndrome. Adolesc Med. 1999;10(2):231–236.
Pasquali R et al. Weight control and its benefits on fertility in women with obesity and polycystic ovary syndrome. Hum Reprod. 1997;12 (Suppl 1):82–87.
Van Dam, E et al. Increase in daily LH secretion in response to short-term caloric restriction in obese women. Am J Physiol Endocrinol Metab. 2001;282:865–872.
Ring. Op cit.
Palomba S et al. Structured exercise training programme versus hypocaloric hyperproteinemic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-233k pilot study. Hum Reprod. 2008;23:642–650.
Bland, J., Introduction to neuroendocrine disorders. Functional Medicine Approaches to Endocrine Disturbances of Aging. Gig Harbor, WA: Functional Medicine Institute; 2001:121.
Kasim Karakas M et al. Metabolic and endocrine effects of a polyunsaturated fatty acid-rich diet in polycystic ovary syndrome. J Clin Endocrinol Metabol. 2004;89(2):615–620.
Chan J et al. Water, other fluids, and fatal coronary heart disease. Am J Epidemiol. 2002;155(9):827–833.
Thys-Jacobs S et al. Vitamin D and calcium dysregulation in the polycystic ovarian syndrome. Steroids. 1999;64(6):430–435.
Nestler J et al. Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. N Eng J Med. 1999;340:1314–1320.
Baillargeon J et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care. 2006;29:300–305.
Gaby A. Nutritional Medicine. Concord, NH: Fritz Perlberg Publishing; 2011:829–831.
Davis A et al. Effect of pinitol treatment on insulin action in subjects with insulin resistance. Diabetes Care. 2000;23:1000–1005.
Ring. Op cit.
Badawy A et al. N-acetyl cysteine and clomiphene citrate for induction of ovulation in polycystic ovary syndrome: a cross-over trial. Acta Obstet Gynecol Scand. 2007;86:218–222.
Rizk S et al. N-acetyl-cysteine is a novel adjuvant to clomiphene citrate in clomiphene citrate-resistant patients with polycystic ovary syndrome. Fertil Steril. 2005;83:367–370.
Low Dog T. The endocrine system. In: Foundations in Herbal Medicine. Albuquerque: Foundations in Herbal Medicine; 2000.
Mills. Op cit.
McKenna D et al. Botanical Medicines: The Desk Reference for Major Herbal Supplements. New York: Haworth Press; 2002.
Wuttke W et al. Chaste tree (Vitex agnus castus): pharmacology and clinical indications. Phytomedicine. 2003;10:348–357.
Westphal L et al. A nutritional supplement for improving fertility in women: a pilot study. J Reprod Med. 2004;49:289–293.
Westphal L et al. Double-blind, placebo-controlled study of Fertilityblend: a nutritional supplement for improving fertility in women. Clin Exp Obstet Gynecol. 2006;33:205–208.
Marchese. Op cit.
Pais P. Potency of a novel saw palmetto ethanol extract, SPET-O85, for inhibition of 5alpha-reductase II. Adv Ther. 2010;27(8):555–563.
Vassiliandi D et al. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2009;94:3558–3566.
Chrubasik J et al. A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: urticae radix. Phytomedicine. 2007;14(7–8):568–579.
Urtica dioica; Urtica urens (nettle) [monograph]. Altern Med Rev. 2007;12(3):280.
Marchese. Op cit.
Nagata C et al. Association of coffee, green tea, and caffeine intakes with serum concentrations of estradiol and sex hormone-binding globulin in premenopausal Japanese women. Nutr Cancer. 1998;30(1):21–24.
Chan C et al. Effect of Chinese green tea on weight, and hormonal and biochemical profiles in obese patients with polycystic ovary syndrome: a randomized placebo controlled trial. J Soc Gynecol Investig. 2006; Jan 13:63–68.
Ibid.
Marchese. Op cit.
Amanini D et al. History of the endocrine effects of licorice. Exp Clin Endocrinol Diabetes. 2002;110(6):257–261.
Amanini D et al. Licorice reduces serum testosterone in healthy women. Steroids. 2005;69:763–66.
Grant P et al. Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. Phytother Res. 2010;24:186–188.
Chen J et al. Maitake mushroom (Grifola frondosa) extract induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination therapy after failure with first-line clomiphene citrate. J Altern Complement Med. 2010;16(12):1295–1299.
Marchese. Op cit.
Yang H et al. Paeoniflorin: an antihyperlipidemic agent from Paeonia lactiflora. Fitoterapia. 2004;7591):45–49.
Hsu F et al. Antihyperglycemic effects of paeoniflorin and S-debenzoylpaeoniflorin, glucosides from the root of Paeonia lactiflora. Planta Medica. 1997;63(4):323–325.
Takahashi K et al. Effects of TJ-68 (shakuyaku-kanzo-to) on polycystic ovarian disease. Int J Fertil Menopausal Stud. 1994;39(2):69–76.
Lim C et al. Current evidence of acupuncture on polycystic ovarian syndrome. Gynecol Endocrinol. 2010;26:473–478.
Stener-Victorin E et al. Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. Am J Physiol. 2009;297:R387–R395.
Eid G et al. Effective treatment of polycystic ovarian syndrome with Roux-en Y gastric bypass. Surg Obes Relat Dis. 2005;1:77–80.

Authors

Alexander Mauskop, MD

View all posts
Anne Richards

View all posts
Aviva Romm, MD

View all posts
Brian Martin, PhD

View all posts
Carolina Stephany Gonzalez, MD

View all posts
Cheri King, ND

View all posts
David Fairbrook, MD

View all posts
Elaine Weil, NP, CNC

View all posts
Howard Straus

View all posts
Marianne Marchese, ND

Marianne Marchese, ND, is the author of 8 Weeks to Women's Wellness. She graduated from the National University of Natural Medicine in 2002. Dr. Marchese maintains private practice in Phoenix, Arizona, and currently teaches gynecology and environmental medicine at Sonoran University of Health Sciences in Tempe, AZ. She has also been adjunct faculty at Southwest College of Naturopathic Medicine and Bastyr University. Dr. Marchese was named in Phoenix Magazine's Top Doctor Issue as one of the top naturopathic physicians in Phoenix several years running. She lectures on topics related to women's health and environmental medicine throughout the US and Canada.

View all posts
Melissa Burchill, RD, CDN

View all posts
Richard S. Lord, PhD

View all posts

Already Subscribed?

Search

Formatting updates are ongoing for older articles.

Author

Alexander Mauskop, MD

Featured Articles

Where are your Clinical Trials?

It has proven to be difficult, if not impossible, to proceed to full-scale randomized controlled trials (RCTs) for most of the natural methods that cannot be patented or otherwise monopolized.

Ralph W Moss, PhD

Uncovering Hidden Health Issues: The Role of Food Sensitivities in Chronic Inflammation and Gut Health

By addressing food sensitivities through targeted testing and personalized dietary interventions, individuals can take a significant step toward reducing inflammation, improving gut health, and enhancing overall well-being.

Cheryl Burdette, ND, Gez Agolli, DrPH PhD MBBS

A Renewed Focus on Self-Help for Healing

As the producer of The Moss Report, the year leading up to the Covid-19 pandemic was filled with anticipation and excitement. We had invested years of hard work and significant resources into two major projects: our feature film, Immunotherapy: The Battle Within, and...

Benjamin Moss

Issue Archives

Event Calendar

October 2026
2026 Women’s Health Summit

October 8 @ 8:00 am - October 10 @ 5:00 pm CDT

La Cantera Resort & Spa 16641 La Cantera Parkway, San Antonio, TX, United States

Setting the Standard for Clinical Excellence From Perimenopause to Power Years: Join the Next Chapter in Women's Health The Women's Health Summit brings together leading clinicians and healthcare professionals for three days of innovative education focused on women's health, hormone balance, menopause, perimenopause, and healthy aging. Explore emerging clinical strategies designed to improve patient outcomes across every stage of a woman's health journey. CME & Continuing Medical Education: Earn CME credits while gaining practical, evidence-based education in women's health, menopause care, hormone replacement therapy, healthy aging, and preventive medicine. Programming is designed to support real-world clinical application and improved patient outcomes.
IMMH 2026

October 8 @ 8:00 am - October 11 @ 5:00 pm PDT

IMMH brings together clinicians, researchers and practitioners for four days of education across trauma, nutrition, metabolism, inflammation, the gut-brain connection, psychedelics, neurodevelopment, neurodegeneration and more — with practical insights you can apply in your work. Access up to 40 CE/CME credits and 60+ hours of expert presentations, workshops, and discussions covering the most important topics in integrative mental health. Your IMMH experience continues beyond the main sessions, with hosted breakfast sessions, Lunch & Learns, evening gatherings, the Expo Hall and informal networking throughout the conference.
NMI Summit 2026

October 9 - October 10

Millennium Gloucester Hotel 4-18 Harrington Gardens South Kensington London, SW7 4LH Millennium Gloucester Hotel 4-18 Harrington Gardens, London, London, United Kingdom

NMI Summit 2026 Longevity and Biological Ageing: Enhancing Health into Advanced Age features scientific and clinical advances relevant to optimising health in the context of biological ageing, chronic disease prevention and helping people enjoy healthier lives as they age.

$445.00

Full Event Calendar

Submit Your Event

← Previous Post Next Post →

Continuous Ketone & Glucose Monitoring Has Arrived: A Milestone for Metabolic Health

By Ben Moss – The FDA has authorized the first wearable device to continuously monitor both glucose and ketones through a single sensor. Developed for diabetes, Abbott’s Libre Duo could have implications extending far beyond it, including nutritional ketosis, metabolic health and metabolic cancer research.

Benjamin Moss Sep 15, 2026

Dandelion Root Extract and Its Therapeutic Potential: From Cancer Biology to Metabolic Health

By Donnie Yance – The body of preclinical research on dandelion root extract reveals intriguing therapeutic potential across oncology, neurology, endocrinology, and general wellness.

Donnie Yance, CN, RH (AHG) Aug 31, 2026

Beyond the Tumor: Terrain, Adaptive Capacity, and Treatment Response in Integrative Oncology

By Rob Lamberton, BSc, FNTP, FDN-P © – The tumor microenvironment — the immediate milieu of stromal cells, vasculature, immune infiltrate, and signaling molecules surrounding a tumor — is well established as a determinant of tumor behavior and treatment response. It is, in effect, a local terrain.

Rob Lamberton Aug 31, 2026

Selenium: The Anti-Cancer Mineral

By Donnie Yance – The future of selenium supplementation lies in moving from one-size-fits-all recommendations to individualized protocols based on genotype, existing health status, baseline selenium levels, and specific disease conditions. With continued research and clinical application, selenium supplementation may become a cornerstone of comprehensive cancer prevention and chronic disease management strategies.

Donnie Yance, CN, RH (AHG) Jun 30, 2026

0 Comments